Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians’ Concerns
The Journal of Law Medicine & Ethics – January 01, 2025
Source: OpenAlex
Summary
A major hurdle for integrating psilocybin treatment into Medicine is the significant risk of medical malpractice liability. Despite promising clinical trials for anxiety and depression, physicians face reluctance due to the hallucinogen's stigma. The absence of established medical standards, standardized training, and clear credentialing for administering psychedelics like psilocybin significantly heightens liability concerns for Psychiatry and Psychology professionals. This lack of defined practice guidelines contributes to potential malpractice claims, hindering psilocybin's therapeutic integration. Addressing these gaps is crucial for realizing its potential in Complementary and Alternative Medicine Studies.
Abstract
Abstract Psychedelic treatment with psilocybin is receiving increased attention following clinical trials showing it may help treat end-of-life anxiety, depression, and several other conditions. Despite this, physicians may be reluctant to prescribe psilocybin and carry out psilocybin treatment because of the stigma surrounding psychedelics and the potential for medical malpractice liability. This paper explores whether psilocybin treatment gives rise to a risk of medical malpractice liability for physicians. Following an overview of psilocybin treatment and its regulatory regime in Canada, exploratory vignettes are used to highlight the relevance and limits of malpractice claims. This paper argues that the lack of established medical standards, standardized training, and credentialing contribute to liability risks surrounding psilocybin treatment. More clinical trials, meta-studies of research analyses, and knowledge sharing will help to develop training programs and medical standards of practice to better realize psilocybin’s potential.